Gambaran Umum
Ocuphire Pharma, Inc., based in the United States, operates within the healthcare sector, primarily focusing on the development of pharmaceutical solutions for eye disorders. The company's robust product pipeline includes several key projects targeting prevalent ocular diseases. Notably, their lead compound, Nyxol Eye Drops, is designed for the treatment of conditions such as night vision disturbances and presbyopia. Alongside this, Ocuphire is advancing other treatments targeting diabetic retinopathy and macular edema, which are significant causes of vision impairment globally. By leveraging innovative research and development strategies, Ocuphire Pharma aims to fulfill unmet medical needs in the ophthalmic field, positioning itself as a key player in the development of novel therapeutics for eye health.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Opus Genetics, Inc. per 2025 Jun 30 adalah 15.42 MM.
- Nilai operating income untuk Opus Genetics, Inc. per 2025 Jun 30 adalah -36.87 MM.
- Nilai net income untuk Opus Genetics, Inc. per 2025 Jun 30 adalah -58.27 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 15.42 | -36.87 | -58.27 |
2025-03-31 | 13.65 | -36.30 | -58.62 |
2024-12-31 | 10.99 | -34.07 | -57.53 |
2024-09-30 | 8.38 | -29.47 | -27.19 |
2024-06-30 | 16.45 | -15.08 | -14.11 |
2024-03-31 | 19.01 | -12.14 | -11.30 |
2023-12-31 | 19.05 | -10.56 | -9.99 |
2023-09-30 | 57.21 | 29.08 | 28.75 |
2023-06-30 | 45.27 | 18.15 | 18.66 |
2023-03-31 | 41.60 | 18.60 | 18.69 |
2022-12-31 | 39.85 | 18.23 | 17.89 |
2022-09-30 | 0.00 | -22.13 | -22.37 |
2022-06-30 | 0.49 | -21.83 | -22.07 |
2022-03-31 | 0.59 | -24.03 | -24.27 |
2021-12-31 | 0.59 | -22.70 | -56.69 |
2021-09-30 | 0.59 | -22.20 | -69.06 |
2021-06-30 | 0.10 | -19.92 | -66.08 |
2021-03-31 | -14.04 | -60.55 | |
2020-12-31 | -9.47 | -24.62 | |
2020-09-30 | -5.29 | -8.28 |
Laporan Laba Rugi: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | -2.02 | -2.02 |
2024-12-31 | -2.15 | |
2024-09-30 | -1.09 | -1.09 |
2024-06-30 | -0.60 | -0.59 |
2024-03-31 | -0.50 | -0.50 |
2023-12-31 | -0.46 | |
2023-09-30 | 1.37 | 1.32 |
2023-06-30 | 0.90 | 0.87 |
2023-03-31 | 0.91 | 0.89 |
2022-12-31 | 0.90 | 0.87 |
2022-09-30 | -1.16 | -1.17 |
2022-06-30 | -1.20 | -1.21 |
2022-03-31 | -1.44 | -1.44 |
2021-12-31 | -3.82 | -3.82 |
2021-09-30 | -5.62 | -5.62 |
2021-06-30 | -7.36 | -7.36 |
2021-03-31 | -9.31 | -9.31 |
2020-12-31 | -5.28 | |
2020-09-30 | -2.31 | -2.31 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Opus Genetics, Inc. per 2025 Jun 30 adalah -31.83 MM.
- Nilai cash from investing activities untuk Opus Genetics, Inc. per 2025 Jun 30 adalah 1.21 MM.
- Nilai kas dari aktivitas pendanaan untuk Opus Genetics, Inc. per 2025 Jun 30 adalah 21.64 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -31.83 | 1.21 | 21.64 |
2025-03-31 | -28.85 | 1.21 | 22.27 |
2024-12-31 | -25.58 | 1.21 | 4.19 |
2024-09-30 | -13.59 | 7.87 | |
2024-06-30 | -11.46 | 12.89 | |
2024-03-31 | -3.18 | 11.36 | |
2023-12-31 | -1.11 | 8.98 | |
2023-09-30 | 23.13 | 5.36 | |
2023-06-30 | 21.64 | 1.32 | |
2023-03-31 | 16.84 | 2.90 | |
2022-12-31 | 14.31 | 3.79 | |
2022-09-30 | -20.12 | -0.10 | 11.83 |
2022-06-30 | -19.21 | -0.10 | 12.10 |
2022-03-31 | -19.73 | -0.10 | 28.48 |
2021-12-31 | -19.37 | -0.10 | 27.61 |
2021-09-30 | -18.08 | 0.54 | 39.07 |
2021-06-30 | -15.55 | 0.54 | 38.40 |
2021-03-31 | -11.88 | 0.54 | 20.68 |
2020-12-31 | -6.80 | 0.54 | 21.12 |
2020-09-30 | -3.58 | -0.00 | 2.57 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/libro untuk Opus Genetics, Inc. pada 2025 Jun 30 adalah 1.77.
- p/tbv untuk Opus Genetics, Inc. pada 2025 Jun 30 adalah 8.37.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | 1.77 | 8.37 | |
2025-03-31 | 1.32 | 1.32 | |
2024-12-31 | 1.03 | 1.03 | |
2024-09-30 | -1.03 | 0.82 | 0.82 |
2024-06-30 | -2.42 | 0.59 | 0.59 |
2024-03-31 | -2.62 | 0.52 | 0.52 |
2023-12-31 | 0.86 | 0.49 | 0.49 |
2023-09-30 | 1.23 | 0.61 | 0.61 |
2023-06-30 | 1.27 | 0.63 | 0.63 |
2023-03-31 | 1.27 | 0.57 | 0.57 |
2022-12-31 | -1.01 | 1.91 | 1.91 |
2022-09-30 | -1.05 | 1.98 | 1.98 |
2022-06-30 | -1.03 | 1.56 | 1.56 |
2022-03-31 | -0.89 | 1.26 | 1.26 |
2021-12-31 | -0.38 | 0.96 | 0.96 |
2021-09-30 | -0.28 | 0.95 | 0.95 |
2021-06-30 | -0.29 | 0.85 | 0.85 |
2021-03-31 | -0.20 | 1.26 | 1.26 |
2020-12-31 | -0.50 | -0.91 | -0.91 |
2020-09-30 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Opus Genetics, Inc. pada 2025 Jun 30 adalah -3.01.
- EBIT (3 tahun) / EV untuk Opus Genetics, Inc. pada 2025 Jun 30 adalah -0.92.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -3.01 | -0.92 |
2025-03-31 | -3.10 | -0.74 |
2024-12-31 | 21.32 | 4.96 |
2024-09-30 | 3.17 | 0.80 |
2024-06-30 | 0.57 | 0.28 |
2024-03-31 | 0.41 | 0.66 |
2023-12-31 | -1.64 | 1.17 |
2023-09-30 | -1.11 | 1.35 |
2023-06-30 | -1.17 | 1.42 |
2023-03-31 | -1.24 | 1.43 |
2022-12-31 | -2.54 | -3.77 |
2022-09-30 | -2.27 | -3.37 |
2022-06-30 | -3.74 | -5.47 |
2022-03-31 | -9.06 | -11.57 |
2021-12-31 | 21.00 | 10.80 |
2021-09-30 | 25.52 | 9.73 |
2021-06-30 | 12.84 | 4.96 |
2021-03-31 | -5.48 | -2.12 |
2020-12-31 | -4.74 | -2.08 |
2020-09-30 |
Efektivitas Manajemen
- roa untuk Opus Genetics, Inc. pada 2025 Jun 30 adalah -1.31.
- roe untuk Opus Genetics, Inc. pada 2025 Jun 30 adalah -1.44.
- roic untuk Opus Genetics, Inc. pada 2025 Jun 30 adalah -2.45.
- croic untuk Opus Genetics, Inc. pada 2025 Jun 30 adalah -0.22.
- ocroic untuk Opus Genetics, Inc. pada 2025 Jun 30 adalah -1.21.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -1.31 | -1.44 | -2.45 | -0.22 | -1.21 |
2025-03-31 | -0.52 | -0.59 | -0.79 | -0.17 | -0.40 |
2024-12-31 | -0.50 | -0.54 | -0.79 | -0.17 | -0.40 |
2024-09-30 | -0.50 | -0.54 | -0.79 | -0.17 | -0.40 |
2024-06-30 | -0.25 | -0.27 | -0.25 | 0.18 | -0.07 |
2024-03-31 | -0.20 | -0.22 | -0.20 | 0.16 | -0.02 |
2023-12-31 | 1.97 | 2.42 | 0.57 | 0.57 | 0.46 |
2023-09-30 | 1.04 | 1.28 | 0.49 | 0.61 | 0.57 |
2023-06-30 | 1.04 | 1.28 | 0.49 | 0.61 | 0.57 |
2023-03-31 | 0.91 | 1.08 | 0.45 | 0.48 | 0.41 |
2022-12-31 | -0.96 | -1.09 | -1.88 | -0.71 | -1.69 |
2022-09-30 | -0.96 | -1.09 | -1.85 | -0.69 | -1.66 |
2022-06-30 | -0.87 | -0.98 | -1.49 | -0.49 | -1.30 |
2022-03-31 | -2.00 | -2.47 | -1.39 | 0.49 | -1.13 |
2021-12-31 | -3.21 | -2.49 | 0.36 | -0.85 | |
2021-09-30 | -25.79 | -3.36 | 1.05 | -0.88 | |
2021-06-30 | -18.88 | -2.93 | 1.04 | -0.69 | |
2021-03-31 | -33.93 | -3.17 | 0.49 | -0.62 | |
2020-12-31 | -13.80 | ||||
2020-09-30 |
Gross Margins
- marjin kotor untuk Opus Genetics, Inc. pada 2025 Jun 30 adalah -1.20.
- marjin bersih untuk Opus Genetics, Inc. pada 2025 Jun 30 adalah -4.29.
- marjin operasi untuk Opus Genetics, Inc. pada 2025 Jun 30 adalah -2.66.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | -1.20 | -4.29 | -2.66 |
2025-03-31 | -1.73 | -3.24 | -3.52 |
2024-12-31 | -1.73 | -3.24 | -3.52 |
2024-09-30 | -0.62 | -3.24 | -3.52 |
2024-06-30 | 0.12 | -0.59 | -0.64 |
2024-03-31 | 0.13 | -0.52 | -0.55 |
2023-12-31 | 0.70 | 0.50 | 0.51 |
2023-09-30 | 0.63 | 0.41 | 0.40 |
2023-06-30 | 0.63 | 0.41 | 0.40 |
2023-03-31 | 0.64 | 0.45 | 0.45 |
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | -31.30 | -45.12 | -44.64 |
2022-03-31 | -26.95 | -41.21 | -40.79 |
2021-12-31 | -24.76 | -96.25 | -38.55 |
2021-09-30 | -12.80 | -117.25 | -37.69 |
2021-06-30 | -62.82 | -660.78 | -199.18 |
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1228627 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |